KRAS and colorectal carcinoma: When the altered cell viabilities between the two cell two lines were compared, KRAS-WT CRC (Hke3) experienced significantly greater cell death compared to KRAS-mut CRC (HCT116) at all time points (p < 0.05) (Table 2), except for a 9-h treatment at 20 μM in which HCT116 had significantly greater cell death, as well as a 24-h treatment at 35 μM in which there was no statistically significant experimental difference (Figure 1).